gsk201211086k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending November 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 

 

 


 
 

 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
14,090,687
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
4,373,486
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
9,717,201
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Share Option Plan - ADS
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
5,537,568
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
10,000,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
7,175,490
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
8,362,078
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome UK Share Option Scheme
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
5,119,750
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number ofsecurities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
5,119,750
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome International Share Option Scheme
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
13,267,156
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
13,267,156
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
Glaxo Wellcome 1999 Share Option Plan
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
1,040,000
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
1,040,000
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
163,606
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
163,606
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
275,420
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
275,420
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
100,000
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less:Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
0
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
100,000
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 

 
 
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an Ris.
 
Date:8 November 2012
 
 
Name of applicant:
GlaxoSmithKline plc
Name of scheme:
GlaxoSmithKline Savings Related Share Option Scheme
Period of return:
From:
1 May 2012
To:
31 October 2012
Balance of unallotted securities under scheme(s) from previous return:
4,005,708
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
115,727
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
3,889,981
         
 
 
Name of contact:
Victoria Whyte
Telephone number of contact:
020 8047 5000
 
 
 
 
 
 
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: November 08, 2012
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc